Zoic Capital
Venture capitalSeed–Series A · 4 people tracked
Investment thesis
Zoic Capital partners with founders developing transformative hard science and frontier technologies backed by robust intellectual property to address well-defined global challenges with measurable impact. The firm targets ventures in their seed through Series A stages, prioritizing early-stage companies that can demonstrate strong market validation and the potential to achieve outsized returns through fundamental improvements over existing solutions.
Source: firm website, verified Jul 21, 2026.
Team · 4 people
from the firm's websiteFounder of Zoic Capital in 2014, Neal has over 15 years of startup experience and previously co-founded Ambature, a superconductor technology company that raised $20M and generated over 3,700 patent claims. He also co-founded HDT Bio, an RNA immunotherapy company with hundreds of millions in government funding. Neal serves as an advisor and board member to multiple startups and mentor at Creative Destruction Labs.
Adrian joined Zoic in 2021 after completing Harvard's Chemical Biology Program. He leads new investment reviews and analysis of over 1,000 health startups annually, oversees investment committee meetings, and develops IP strategy for portfolio companies. Adrian also serves as a Scientific Advisor to Creative Destruction Labs.
Ian has been with Zoic since its founding in 2014. He led early fundamental analysis and crafted the firm's foundational investment thesis emphasizing 10X improvements. Ian has evaluated over 3,000 life sciences companies, serves on multiple boards, and oversees firm operations including investment contracts, workflows, and security protocols.
Shayan joined Zoic as a Venture Partner in 2022, bringing 20 years of operational and investment experience across the healthcare ecosystem. He holds degrees in engineering and healthcare economics, with background in medical devices, analytics, and digital health services spanning roles at UnitedHealth Group, Blue Health Intelligence, Boston Scientific, and Medtronic.
Frequently asked questions
- What stage does Zoic Capital invest at?
- Zoic Capital invests at the Seed, Series A stages.
- What sectors does Zoic Capital focus on?
- Zoic Capital focuses on Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.
Similar investors
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.
Innovestor is a Finnish investment manager that operates across venture capital, real estate, and energy storage sectors. The firm invests in early-stage technology and life science startups, energy-efficient commercial real estate, and battery storage and solar solutions. Innovestor also provides corporate venturing advisory services.
Khosla Ventures is a technology-focused investment firm that seeks companies leveraging disruptive technological advances to solve large-scale problems across multiple industries. The firm emphasizes proprietary technology, business model innovation, and early-stage, bold investments with unfair advantages.
An early-stage venture capital firm investing in technology founders building solutions across multiple sectors.